Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Joseph Jurcic, Chairman of Actinium's Clinical Advisory Board, will participate in the "Combination Therapy: Proposals for Success" panel discussion at the Cancer Advan
Dublin- Research and Markets has announced the addition of the "Biopharmaceutical and Vaccine Production Markets" report to their offering. Though biotechnology has created many new therapies and vaccines- including products to treat cancer, diabetes, HIV/AIDS and autoimmune disorders- there are still huge challenges during the final stages of clin
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it had reached an exclusive development and licensing agreement with privately held biopharmaceutical company, Cingulate Therapeutics, to support the development..
CANTON, MA/ ACCESSWIRE/ September 23, 2014/ Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that U.S. Collegium recently announced positive Phase 3 study results for Oxycodone DETERx (R) and expects to submit an NDA in the fourth quarter of 2014. The product has been designated Fast Track Status by the FDA.
CANTON, MA, United States, via ETELIGIS INC., 09/23/2014 Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that U.S. Collegium recently announced positive Phase 3 study results for Oxycodone DETERx and expects to submit an NDA in the fourth quarter of 2014. The product has been designated Fast Track Status by the
Credence MedSystems, Inc. announced today the launch of the Credence Companion Safety Syringe System at two upcoming conferences focused on drug delivery solutions. The Companion results from the Credence team s intense desire to improve patient care by understanding and addressing the needs of both the end-user performing the injection as well
The meeting will focus on scientific and technical issues related to the development and in vitro assessment of these products, as well as FDA's approach towards assessing the benefits and risks of all opioid medications, including those with abuse-deterrent properties. FDA is seeking input on these issues from all stakeholders, including patients,
DGAP-News: 4 SC AG/ Key word: Miscellaneous Press Release: 4 SC's partner Yakult Honsha completes Phase I part of clinical study with resminostat in Asian HCC patients and starts randomised Phase II part 23.09. 2014/ 07:30- Press Release 4 SC's partner Yakult Honsha completes Phase
Press Release: 4 SC's partner Yakult Honsha completes Phase I part of clinical study with resminostat in Asian HCC patients and starts randomised Phase II part DGAP-News: 4 SC AG/ Key word: Miscellaneous Press Release: 4 SC's partner Yakult Honsha completes Phase I part of clinical study with resminostat in Asian HCC patients and starts randomised
EOS imaging reported that its next-generation sterEOS 3 D imaging software, sterEOS 1.6, has received 510 clearance from the U.S. Food and Drug Administration. Concurrent with the FDA clearance, the benefits of EOS and its software sterEOS were highlighted at the 49th Annual Meeting of the Scoliosis Research Society in Anchorage, Alaska and during
Vivus and Auxilium Pharmaceuticals reported that the U.S. Food and Drug Administration has approved a supplemental new drug application for Stendra. According to a media release, Stendra is now the only FDA- approved erectile dysfunction medication indicated to be taken as early as approximately 15 minutes before sexual activity. "Stendra is the f
Rinovum Women's Health announced today that The Stork OTCthe only home-use conception assistance device on the market cleared by the FDA for over-the-counter salesis available without a prescription in stores and online at http://www.storkotc.com. It is the only FDA- cleared product that provides consumers a safe, easy way to perform cervica
Dr. Lim will participate in a panel discussion on the topic of "Novel Science Developments: Precision Medicine," moderated by Bill Rastetter, Ph.D., Former Executive Chairman of Biogen Idec and Former Chairman and CEO of Idec Pharma, at the Leerink Healthcare Leadership Summit on September 18, in Napa, California. Dr. Lim will also be part of a pan
Ivantis, developer of the novel Hydrus Microstent device designed to lower eye pressure for glaucoma patients, announced today that it secured an additional $25 MM in its Series B financing. The latest close in the Series B includes new investor Foresite Capital, plus returning investors New Enterprise Associates, Delphi Ventures, Ascension Venture
ALEXANDRIA, Va., Sept. 23 Mystic Pharmaceuticals, Austin, Texas, has been assigned a patent developed by Christopher D. Shay, Horseshoe Bay, Texas, and Timothy R. Sullivan, Austin, Texas, for "medical devices for dispensing powders." The patent application was filed on March 29, 2012. Written by Sudarshan Harpal; edited by Jaya Anand.
By a News Reporter-Staff News Editor at Cancer Weekly A new study on Clinical Research is now available. Our news editors obtained a quote from the research from Moffitt Cancer Center, "The literature relating to cancer treatment in the older patient population was reviewed. The news editors report that additional information may be obtained by c
Noxxon Pharma has appointed Don Munoz to the newly created position of Chief Financial Officer. According to a release, before joining Noxxon Pharma, Don was Head of Investment Banking at Summer Street Research Partners, an investment banking and institutional securities firm focused exclusively on healthcare. He also spent approximately 10 years i
By a News Reporter-Staff News Editor at Cancer Weekly From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Wang, Shudong; Chahrour, Osama; Lu, Tiangong; Hu, Anran, filed on June 21, 2011, was published online on September 9, 2014. The patent's assignee for patent number 8829003 is Changzhou Le Sun Pharmaceuticals Li
By a News Reporter-Staff News Editor at Life Science Weekly Fertin Pharma A/S has been issued patent number 8828361, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. The patent's inventor is Andersen, Carsten. This patent was filed on July 23, 2013 and was published online on September 9, 2014.
Release date- 22092014- WAUKESHA, Wis.- GE Healthcare today announced U.S. FDA 510 clearance of its Discovery* IQ PET/CT system, enabling both outstanding image quality and intelligent quantitation to help physicians deliver the best possible patient outcomes. 'By 2020, it's estimated that 50% of people will develop cancer at some point in their li
The Pharmaceutical or Biotech Company of the Year went to Eli Lilly and Company, and Steven Millerman, CEO of Prime Access, was named the Trailblazer Marketer of the Year for his exceptional work revolutionizing multi-cultural healthcare communications. This year's PM360 Lifetime Achievement Award went to that Ron Pantello, Founder of Lally, McFarl
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that a team of researchers led by Shari Pilon-Thomas, PhD from the Moffitt Cancer Center will present data at the Society for Immunotherapy of Cancer 29 th Annual Meeting with an abstract titled Efficacy of Intralesional...
OTTAWA- Botox maker Allergan Inc. is in advanced talks to buy Salix Pharmaceuticals Ltd. in order to fend off a $53 billion hostile bid from Canada- based Valeant Pharmaceuticals Inc., according to media reports on Monday. Irvine, California- based Allergan's acquisition of Salix would likely halt a hostile bid for the company from Valeant Pharma a
Titan Pharmaceuticals, Inc. today announced that patient enrollment in the Phase 3 study of Probuphine , the company's investigational subdermal implant for the maintenance treatment of opioid dependence, has reached the halfway mark. Titan's partner, Braeburn Pharmaceuticals, is sponsoring the study and expects it to be fully enrolled before the
By a News Reporter-Staff News Editor at Cardiovascular Week A patent application by the inventors Braeckman, Rene; Stirtan, William; Soni, Paresh, filed on February 28, 2014, was made available online on September 11, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned